Ying Cui

I joined NDORMS in Sep 2022 as the Trainee Clinical Trial Manager for the IMPROVE study. This study is to investigate immune response to COVID-19 vaccination in chronic lymphocytic leukaemia patients taking Bruton Tyrosine Kinase inhibitors (BTKi) drugs. This research will help us to understand if pausing BTKi therapy for 3 weeks can improves the antibody response to vaccination and to see how well this is tolerated.

Prior to joining NDORMS, I worked for the Oxford Centre for Histopathology Research at the Nuffield Department of Surgical Sciences (NDS). I facilitated the pipeline progress of spatial transcriptomics study (SPACE) and pathology digitalisation study (ProMPT) on prostate cancer. For this post, I achieved Awards for Excellence from NDS. During COVID pandemic, I worked on a secondment as a Clinical Trial Administrator on EMPA-KIDNEY study in Clinical Trial Service Unit. I accelerated the set-up and running for the China and Malaysia regions and ensured agreed study milestones were met.

Before moving into the field of clinical trials and biobanking, I was a scientist in lab-based research for over 10 years. I gained my medical degree (MBBS) and MSc from Sun Yat-sen University in Guangzhou, China after which I moved to Oxford, UK and gained my D. Phil in Physiology in Brasenose College, University of Oxford.

Outside of my work I enjoy cycling and walking in the hills because that enables me to keep myself fit physically and mentally. Community is very important to me: over the last two years, I have organized and fundraised to purchase, deliver, and donate certified PPE to the NHS, including face shields to OUH and masks to St Andrew’s Care Home in Headington. I was a volunteer translator for DXY Open Course for Covid-19 related clinical diagnosis and treatment experience sharing for DXY Open Course video in 2020.